Zacks Investment Research downgraded shares of THRESHOLD PHARM (THLD) from OUTPERFORM to NEUTRAL on October 05, 2012, with a target price of $8.40.
Threshold is focused on the discovery, development, and commercialization of small molecule therapeutics based on "Metabolic Targeting." This approach targets abnormal glucose metabolism – a fundamental property of most solid tumors and other diseases. The company's initial focus is the treatment of cancer and benign prostatic hyperplasia, a disease characterized by overgrowth of the prostate.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on THRESHOLD PHARM (THLD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment